Healthcare entity

Hims & Hers Health, Inc.

Company HIMS

Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention American Society of Plastic Surgeons, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.

Last mentioned: Aug 1, 2026

Entity pulse

Recent coverage · Hims & Hers Health, Inc.

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Hims & Hers Health, Inc.

Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention American Society of Plastic Surgeons, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.9. We currently track 1 Healthcare story that mention Hims & Hers Health, Inc., all published on March 4, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Hims & Hers Health, Inc.. Shared-story counts are live from our verified record — not editorial picks.

Key Data

ticker
HIMS
name
Hims & Hers Health, Inc.
price
12.5
change
-1.2
changePct
-8.7

Timeline

  1. Aesthetic Market Realignment

    Dermal filler and plastic surgery volumes hit record highs as patients seek to correct skin laxity post-weight loss.

  2. Telehealth Pivot

    Major digital health platforms launch dedicated GLP-1 programs with compounded options to address shortages.

  3. The 'Ozempic Face' Viral Trend

    Social media and news outlets begin highlighting the aesthetic side effects of rapid weight loss.

  4. Wegovy Launch

    FDA approves semaglutide specifically for chronic weight management, sparking mainstream interest.

  5. Ozempic Approval

    FDA approves semaglutide for Type 2 diabetes, marking the start of the GLP-1 era.

Stories mentioning Hims & Hers Health, Inc. 1

Hims & Hers Health, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.